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being assessed by means of the Abnormal Involuntary Move- 
ment Scale (AIMS). 
In a preliminary evaluation we analyzed the data from the 
first 16 patients that completed the study (6 male, IO female, 
age S1.6* 18.6 years). We found a significant improvement in 
older patients (age> 40 years) on alpha-tocopherol as compared 
to the placebo group (p < 0.05). No therapeutic effects of alpha- 
tocopherol were observed in the younger patients (age<40 
years). 
Up to now age is the only valid risk factor which increases 
vulnerability for TD. Because the content of alpha-tocopherol 
in the brain is known to decrease with age, it is tempting to 
speculate that (1) the decrease of brain alpha-tocopherol with 
age enhances the susceptibility of elder individuals to the 
damaging effects of free radicals, resulting in increased suscep- 
tibility to neuroleptic-induced TD, and that (2) therefore these 
elder patients might benefit from high-dose alpha-tocopherol 
therapy, as found in the present study. However, this working 
hypothesis certainly needs confirmation in a larger sample 
before any definite conclusion can be drawn. 
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Tardive dyskinesia (TD) is a hyperkinetic motor disorder 
which is thought to be secondary to neuronal changes following 
chronic receptor blockade by neuroleptics in the basal ganglia. 
Recently it has been suggested that the process is reversible if 
the dopamine (DA) blockade is removed. To further explore 
this issue we carried out a long term follow up (mean= 13.1 
months) of 20 TD patients (mean age 43.7* 16.1 years), who 
had been withdrawn from their neuroleptic treatment during 
the follow up period. 
The study demonstrated that 13 patients (65%) showed a 
decrease in TD, two (10%) did not demonstrate any change 
and five (25%) had worsening TD. Overall, there was a 
significant decrease in TD (paired t-test, p=O.O118). The 
average reduction of TD was 17.9% k 34.7 overall, but in these 
13 patients who improved, the reduction was 37.1% k22.3. 
Significant predictors of decrease in TD included length of 
withdrawal period (partial r = 0.63, p <: 0.0 I), male gender (r = 
0.76, p < O.OOl), and higher baseline TD score (partial r= 0.78, 
p=O.OOl). 
The results strongly suggest that TD is reversible, although 
it is not reversible in all cases. Further, since neuroleptic 
withdrawal is not always possible, the results emphasize the 
utility of atypical neuroleptics (e.g. clozapine), which exert low 
or no DA receptor blockade in the basal ganglia. 
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Incidence figures for neuroleptic-induced akathisia (NIA) 
range from 25 to 75% in the literature. This discrepancy is 
mainly due to differential diagnostic approaches of the syn- 
drome. All the authors reporting lower incidence figures stress 
the objective phenomena of NIA, reports that emphasize the 
subjective component find higher rates. We present a prelimi- 
nary analysis of an ongoing drug monitoring program of 
antipsychotic drugs. So far, SS patients have been evaluated 
using various side effect rating scales including the Hillside 
Akathisia Scale. 40% of the sample scored higher than two 
(small amplitude movements, part of the time) or more on the 
objective part of the scale, a subjective rating of two (subjective 
symptoms present and easily controlled) or more was found in 
54.28%. Assuming that both phenomena are necessary for the 
valid diagnosis of akathisia we calculated an incidence of 28.6% 
(95% confidence intervals, 14.6-46.5%). All patients had devel- 
oped NIA by the third day of antipsychotic treatment. Our 
results are comparable to those of earlier reports and reempha- 
size the need of recognition and adequate treatment of this 
distressing side effect of antipsychotic drugs. 
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The tolerance to neuroleptic therapy with regard to the 
development of extrapyramidal side-effects (EPS) varies widely 
among schizophrenic patients. The individual vulnerability 
threshold to EPS has recently been shown to remain stable 
over time. A number of studies reported an increased occur- 
rence of EPS in patients with structural brain abnormalities as 
assessed by computertomography. Similarly, a poorer perfor- 
mance in motor dexterity tests was shown in schizophrenics 
with abnormal CT findings. These data suggest that poor 
